Keywords: Alnylam, ALN-RSV01, Ph IIb, RSV, Respiratory syncial virus

Alnylam's RSV drug candidate misses primary endpoint in Ph IIb

Article | 31 May 2012

Leading USA-based RNAi therapeutics firm Alnylam Pharmaceuticals (Nasdaq: ALNY) yesterday announced disappointing top-line results from a Phase IIb trial with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Alnylam Pharmaceuticals

Go to company listing